Welcome to our dedicated page for Merck & Co SEC filings (Ticker: MRK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Merck & Co., Inc. (NYSE: MRK) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, along with AI-powered summaries to help interpret complex documents. Merck is a New Jersey–incorporated biopharmaceutical preparation manufacturer whose common stock and multiple series of notes are registered on the New York Stock Exchange, as reflected in its Form 8-K filings.
Through this page, readers can review Merck’s current and historical filings, including Form 8-K reports on material events such as public offerings of long-dated notes under its automatic shelf registration statement on Form S-3ASR and announcements of restructuring programs. Filings related to quarterly and annual results, such as earnings releases furnished on Form 8-K, give additional context on the company’s financial condition and performance.
For a research-intensive company like Merck, core SEC filings such as annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) are key sources for information on its human health and animal health businesses, major products like KEYTRUDA and GARDASIL, pipeline programs including WINREVAIR and Alzheimer’s disease candidates, risk factors and capital structure. Forms 3, 4 and 5, when filed, provide details on insider transactions by directors and officers.
Stock Titan enhances these filings with AI-generated explanations that highlight important sections, clarify technical language and point out items that may interest investors, such as new debt issuances, restructuring charges or significant acquisitions. Real-time updates from EDGAR help ensure that newly filed Merck documents, including 10-Ks, 10-Qs and Form 4 insider reports, appear promptly, allowing users to track regulatory disclosures related to MRK in a single, organized feed.
Merck & Co., Inc. director Christine E. Seidman received a grant of 67.5451 phantom stock units on March 31, 2026. These units track Merck common stock on a 1-for-1 basis at a reference value of $120.29 per unit.
The phantom stock units are to be settled 100% in cash upon her termination of service under the Plan for Deferred Payment of Directors' Compensation. Following this grant, her phantom stock holdings total 19,238.3277 units, and she also holds 100 shares of Merck common stock, including shares acquired through dividend reinvestment transactions.
GLOCER THOMAS H reported acquisition or exercise transactions in this Form 4 filing.
Merck & Co., Inc. director Thomas H. Glocer received a grant of 405.2706 phantom stock units on March 31, 2026, credited at $120.29 per unit on a 1-for-1 basis with common stock. These phantom units are payable 100% in cash after his board service ends under the deferred compensation plan. He also reports direct ownership of 5,100 shares of Merck common stock, including shares accumulated through dividend reinvestment.
Merck & Co., Inc. director Mary Ellen Coe received a grant of 249.3973 phantom stock units on common stock equivalents. The units were awarded at a reference price of $120.2900 per unit and are structured on a 1-for-1 basis with Merck common stock.
The phantom stock units are to be settled 100% in cash upon Coe’s termination of service, following a distribution schedule elected under the Plan for Deferred Payment of Directors' Compensation. After this award, her phantom stock holdings total 29,702.6519 units. A separate holding entry shows she directly owns 10 shares of Merck common stock, including shares acquired through dividend reinvestment transactions.
The Vanguard Group filed Amendment No. 11 to its Schedule 13G/A reporting 0 shares of Merck & Co., Inc. common stock. The amendment states that, following an internal realignment on January 12, 2026, certain subsidiaries will report beneficial ownership separately in reliance on SEC Release No. 34-39538. The form is signed by Ashley Grim on 03/27/2026.
Merck & Co., Inc. executive Brian Foard, EVP, Specialty, Pharma, & ID, filed an initial statement of beneficial ownership on Form 3. The filing does not list any transactions or current holdings entries, serving mainly as a regulatory record of his status as a company officer.
Merck & Co., Inc. reported 2025 total sales of 65,011 million, slightly above 64,168 million in 2024, driven by its Pharmaceutical segment at 58,142 million and Animal Health at 6,354 million. Oncology remains the main growth engine, with Keytruda/Keytruda Qlex sales rising to 31,680 million from 29,482 million, while Gardasil/Gardasil 9 declined to 5,233 million from 8,583 million.
The company details an extensive portfolio across oncology, vaccines, hospital acute care, cardiometabolic, virology, neuroscience, diabetes and animal health, supported by broad global approvals in 2025–early 2026 for Keytruda, Keytruda Qlex, Capvaxive, Enflonsia, Gardasil 9, Welireg, Winrevair and multiple animal health brands.
Merck also highlights mounting pricing and access pressures, including the U.S. Inflation Reduction Act drug price setting for Januvia, Janumet, Janumet XR and Lenvima, a three‑year most‑favored‑nation agreement with the U.S. government, and the expectation that Keytruda will enter government price setting in 2029, after which U.S. Keytruda sales are expected to decline materially.
Merck & Co. submitted a Form 13F holding report. The report lists 12 Form 13F information-table entries with a total market value of $276,276,803. The filing was signed by Kelly Grez, Corporate Secretary in Rahway, NJ on 02-17-2026.
The filing shows a planned sale of 20,000 shares of Merck (MRK) common stock through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of 2,368,202.00. Merck had 2,482,022,536 common shares outstanding at the time of this notice.
The seller, identified as Chirfi Guindo, previously sold 20,000 common shares on 02/05/2026 for gross proceeds of 2,437,676.00. The shares to be sold were acquired through restricted stock vesting under a registered plan on several dates between 08/03/2023 and 01/27/2025. By signing, the seller represents they are not aware of undisclosed material adverse information about Merck.
Merck & Co., Inc.’s Chief Marketing Officer, Chirfi Guindo, reported an open-market sale of company stock. On 02/12/2026, he sold 10,000 shares of Merck common stock at a weighted average price of $121.4562 per share, through multiple trades in a narrow price range.
After this transaction, Guindo directly beneficially owned 60,615.127 shares of Merck common stock. The filing notes that detailed trade-by-trade pricing within the $121.4400 to $121.5150 range is available upon request.
Merck & Co. insider transaction notice: A person filing for Merck (MRK) plans to sell 10,235 common shares through Morgan Stanley Smith Barney LLC on or about 02/10/2026 on the NYSE, with an aggregate market value of 1202843.81.
The shares to be sold were acquired as restricted stock vesting under a registered plan on 01/26/2026, in the same amount of 10,235 shares. Over the past three months, an individual named Dean Li sold 15,087 Merck common shares on 02/04/2026 for gross proceeds of 1791824.15.